By Measuring The Ability To Specifically Bind A Target Molecule (e.g., Antibody-antigen Binding, Receptor-ligand Binding, Etc.) Patents (Class 506/9)
  • Patent number: 10809266
    Abstract: Provided herein are compositions and methods for the identification of an expression profile in a single cell or population of cells. Kits for use with the disclosed methods are also provided, including antibodies, with a unique molecular identifier and antibody identifier, and primers for amplification of the antibody identifier sequence.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: October 20, 2020
    Assignee: VERILY LIFE SCIENCES LLC
    Inventors: Ian Peikon, Gary Tong, Daniel Liu, Ci Chu
  • Patent number: 10808017
    Abstract: 53BP1 inhibitors, compositions comprising the inhibitors and methods of using same are provided. The inhibitors can be used in combination with gene editing systems.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: October 20, 2020
    Assignees: The Governing Council of the University of Toronto, Sinai Health System
    Inventors: Daniel Durocher, Sachdev Sidhu, Wei Zhang, Frank Sicheri, Marella Canny
  • Patent number: 10809262
    Abstract: The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. A method for analyzing colon cancer markers using multiplex colon cancer marker panel.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 20, 2020
    Assignees: Shimadzu Corporation, Osaka University
    Inventors: Makoto Watanabe, Eiichi Matsuo, Naoki Kaneko, Toshiya Matsubara, Osamu Nishimura, Masaki Mori, Hideo Matsuda, Shigeto Seno, Ichiro Takemasa
  • Patent number: 10794856
    Abstract: A detection stage of an electronic detection device, for example a pH meter, includes an insulating region that receives an element to be analyzed. The insulating region is positioned on a sensing conductive region. A biasing stage includes an electrically conductive region which is capacitively coupled to the conductive region. The electrically conductive region is formed in an uppermost metallization level along with a further conductive region. That further conductive region is electrically connected to the sensing conductive region by a via passing through an insulating layer which insulates the electrically conductive region from the sensing conductive region.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: October 6, 2020
    Assignee: STMicroelectronics (Crolles 2) SAS
    Inventors: Getenet Tesega Ayele, Stephane Monfray
  • Patent number: 10787666
    Abstract: Provided methods for diagnosing and treating cancer by reducing the biological activity and/or expression of P-element induced wimpy testis-like protein 4 (PIWIL4), and related compositions and methods.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 29, 2020
    Assignee: ShanghaiTech University
    Inventors: Haifan Lin, Zifeng Wang, Sanhong Liu, Shuo Shi
  • Patent number: 10788446
    Abstract: A semiconductor device includes a first passivation layer disposed on a semiconductor base. The semiconductor device further includes a dielectric layer disposed on the first passivation layer. The semiconductor device further includes a plurality of pillars disposed in an opening in the dielectric layer and the first passivation layer and from a top surface of the semiconductor base. The semiconductor device further includes a metal layer disposed on the exterior surfaces of the plurality of pillars and sidewalls of the dielectric layer and the first passivation layer and on the exposed top surface of the semiconductor base. The semiconductor device further includes a second passivation layer disposed on the metal layer and a top surface of the semiconductor device; wherein the second passivation layer has an electrical charge.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: September 29, 2020
    Assignee: International Business Machines Corporation
    Inventors: Juntao Li, Kangguo Cheng, Ruilong Xie, Chanro Park
  • Patent number: 10781471
    Abstract: The present invention encompasses the recognition that identification of alternative means to block RAS oncogenic signaling may be required for developing novel cancer therapies. Among other things, the present invention encompasses the recognition that targeting RAS palmitoylation can achieve effective therapy for RAS-related cancers. Furthermore, the present invention encompasses the recognition that reduction of ZDHHC9 level and/or activity can significantly reduce palmitoylation level of Ras protein. Among other things, the present invention encompasses the recognition that identification of agents that modulate expression and/or activity of ZDHHC9 can reduce palmitoylation level of Ras protein. In some embodiments, the present invention provides methods of treating a subject suffering from cancer by administering ZDHHC9 inhibition therapy.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: September 22, 2020
    Assignees: Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Brandeis University
    Inventor: Ruibao Ren
  • Patent number: 10774323
    Abstract: The present invention relates to methods for displaying cyclic peptides on the surface of bacteriophage particles and collections thereof.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: September 15, 2020
    Assignee: LANTHIOPEP B.V.
    Inventors: Johannes Herbert Urban, Markus Andreas Moosmeier, Tjibbe Bosma, Josef Prassler
  • Patent number: 10766953
    Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 8, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Marc Mercken, Thomas Malia, Marianne Borgers, Kristof Van Kolen
  • Patent number: 10760132
    Abstract: The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: September 1, 2020
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, George Konstantine Michalopoulos, Joel B. Nelson, Chi Song, Chien-Cheng Tseng, Yanping Yu
  • Patent number: 10759821
    Abstract: Described herein are trehalose analogues. Also described herein are methods of making the trehalose analogues and uses of the analogues. For example, the disclosed trehalose analogues may be useful in the detection of bacteria.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: September 1, 2020
    Assignee: CENTRAL MICHIGAN UNIVERSITY
    Inventor: Benjamin M. Swarts
  • Patent number: 10753859
    Abstract: Provided herein are IEF focusing methods for determining the number of drug molecules present in at least one antibody-drug conjugate (ADC) species subpopulation. In one embodiment, the method comprises performing free solution isoelectric focusing on a sample comprising at least one ADC species, to obtain a focused sample. The absorbance of the sample at two different wavelengths is then measured, for example, over a range of pI values. Absorbance values at the two different wavelengths are compared at at least one corresponding pI value, where the at least one corresponding pI value is the pI of the ADC subpopulation. The number of drug molecules in the at least one ADC species subpopulation is then determined based on the comparison. The methods provided herein can also be used to determine the number of specific binding pair members bound to its target specific binding pair member.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: August 25, 2020
    Assignee: ProteinSimple
    Inventor: Jiaqi Wu
  • Patent number: 10746656
    Abstract: The present disclosure discloses a CO2 quantitative fluorescent sensing material, a preparation method and an application thereof. The preparation method for the CO2 quantitative fluorescent sensing material includes dissolving 9,10-diacrylic anthracene in a solvent to prepare 5-10 mg/mL of a first solution; dissolving MnCl2 or Mn(ClO4)2 in water to prepare 50-100 mg/mL of a second solution; mixing the first solution and the second solution; adding a diluted acid into the mixed solution; sealing and heating the mixed solution. This preparation method is simple. During application, an ionic liquid produced by a reaction of CO2 gas and an amine compound improves an aggregation-induced emission of the CO2 quantitative fluorescent sensing material and a fluorescence thereof is significantly improved. So that a fluorescent CO2 quantification is performed rapidly and accurately.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 18, 2020
    Assignee: Yancheng Institute of Technology
    Inventors: Minghua Xie, Xiuli Yang, Rong Shao, Guihua Hou, Rongfeng Guan
  • Patent number: 10738284
    Abstract: Variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: August 11, 2020
    Assignees: Regeneron Pharmaceuticals, Inc., University of Maryland, Baltimore
    Inventors: May Montasser, Cristopher Van Hout, Alan Shuldiner, Giusy Della Gatta, Matthew Healy, Marja Puurunen
  • Patent number: 10739351
    Abstract: Provided herein are method and kits for elucidation of immunological repertoires (comprising functional pairs of immune cell receptors and antigens). In some embodiments, an immune cell receptor and an antigen that it binds to are isolated, and sequence information is obtained about the immune cell receptor and antigen. In some embodiments, an antigen expressed on a first cell and an immune cell receptor expressed on a second cell can form a synapse, mRNAs can be isolated from the resulting doublet of cells, and sequences of the functional immune cell receptor and its antigen can be obtained from the mRNAs.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: August 11, 2020
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Devdoot Majumdar, Anirudh Mathukumilli, David Baltimore
  • Patent number: 10732092
    Abstract: The present invention relates to a method and system for analyzing mechanical signatures of a plurality of cells for metastatic detection. Specifically, a data set characterized by at least one metric (such as Brillouin frequency shift and/or Brillouin linewidth) representing a cell mechanical signature is acquired for the plurality of cells by using a label-free Brillouin spectroscopy. A merit function is calculated based on one or more statistical characteristics of the data set, such as sensitivity and specificity. Then, the plurality of cells can be classified to detect metastatic cells based on mechanical signatures provided by the data set and an optimal metric value delivering maximum to the merit function.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: August 4, 2020
    Assignee: University of Maryland, College Park
    Inventors: Giuliano Scarcelli, Jitao Zhang
  • Patent number: 10729818
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 4, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Patent number: 10722531
    Abstract: Improved methods for treating cancer are provided herein by determining if a cancer patient, particularly a colon cancer patient or a gastric cancer patient, will clinically respond in a favorable manner to a therapeutic strategy comprising the FOLFOX regimen (fluorouracil, leucovorin, and oxaliplatin) or a combination of capecitabine and cisplatin. Diagnostic methods for measuring the OPRT, TYMP, and/or UCK2 proteins in a tissue sample, such as a tumor sample, from the patient are provided.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 28, 2020
    Assignee: NantOmics, LLC
    Inventors: Todd A. Hembrough, Fabiola Cecchi, Dongyao Yan
  • Patent number: 10724034
    Abstract: The present application provides a method of synthesizing a genetically-encoded chemical modification of a peptide library. A vector in a substrate, such as a phage, is modified to include a peptide linker and a modification to form a genetic “barcode”. The barcode is screened against potential targets which may be used in drug discovery.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: July 28, 2020
    Inventors: Ratmir Derda, Pavel Kitov, Simon Ng, Katrina Felicia Tjhung, Daniel Ferrer Vinals
  • Patent number: 10718003
    Abstract: Accurate measurements of the presence or absence of an analyte (e.g., MRSA) in a sample are provided. For example, the sample can be subjected to an activation reagent (potentially after an initial reagent has already been added), which can cause a flash signal that increases and then decreases over time. Signal data points can be measured from the flash signal using a detector. A quadratic regression function that fits the signal data points can be determined. An accuracy of the quadratic fit can be determined, as well as a signal-to-background ratio. A difference between a signal-to-background term and an accuracy term can be used as a score that is compared to a threshold to determine whether the analyte is present in the sample.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: July 21, 2020
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Diego Ariel Rey, Paul Hayter, Manoj Sharma, Nick Reinig
  • Patent number: 10709767
    Abstract: A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 14, 2020
    Assignees: KINKI UNIVERSITY, ASAHI KASEI PHARMA CORPORATION
    Inventors: Atsufumi Kawabata, Hideaki Suzuki
  • Patent number: 10714326
    Abstract: This disclosure provides systems, methods, and apparatus related to laser ablation spectrometry systems. In one aspect, a system comprises a microscope, a laser, a continuous flow probe, and a gas confinement device. The laser is positioned to emit light through an objective lens of the microscope. The continuous flow probe is coupled to a spectrometer. An end of the continuous flow probe is positioned proximate a sample and between the sample and the objective lens. The gas confinement device defines a gas inlet, a chamber, a platform, a wall surrounding the platform, a plurality of vents, and a plurality of channels. Each of the plurality of vents is positioned to direct a gas substantially parallel to the platform, and each of the plurality of vents is defined in the wall. The plurality of channels is operable to provide fluid communication between the chamber and the plurality of vents.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: July 14, 2020
    Assignee: The Regents of the Unversity of California
    Inventors: Hoi-Ying N. Holman, Antoine Masson, Evan Williams
  • Patent number: 10704093
    Abstract: Gene expression is measured in a sample of peripheral blood mononuclear cells (PBMCs) obtained from a subject and used to predict organ function recovery. A Function Recovery Potential (FRP) score is assigned to a sample that reflects the measured expression level of the genes identified herein in a direction associated with recovery from organ failure. Treatment of the subject with optimal medical management (OMM) and/or palliative care (PC) is advised when the FRP score is lower than the reference value, and referring the subject for treatment with therapies including—but not limited to—mechanical circulatory support (MCS) surgery, heart transplant (HTx) surgery, or other intervention for advanced heart failure is advised when the FRP score is greater than the reference value. A method for developing an FRP scoring algorithm that predicts a subject's ability to recover from medical intervention for organ failure is also described.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: July 7, 2020
    Assignee: THE REGENTS OF THE UNIVERSTIY OF CALIFORNIA
    Inventors: Mario Deng, Galyna Bondar
  • Patent number: 10705083
    Abstract: The present disclosure relates to a method for characterizing and identifying a bioparticle. The method comprises introducing the sample to a substrate having a surface comprising a plurality of binding sites whereon bioparticles can be bound, determining, for at least one temperature, data representative for the interface thermal resistance of the surface of the substrate sufficiently long to include the detachment process of the bioparticles, and deriving, for the at least one temperature, a bioparticle retention time and/or detachment rate from the data representative for the interface thermal resistance data. The present disclosure also relates to a bio-sensing device suitable for the detection and/or characterization of target bioparticles.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: July 7, 2020
    Assignee: IMEC VZW
    Inventors: Patricia Losada-Pérez, Derick Yongabi, Mehran Khorshid, Ward De Ceuninck, Ronald Thoelen, Patrick Wagner
  • Patent number: 10704092
    Abstract: Provided herein is a multi-sample and multi-locus method for analyzing a genetic locus. In particular, provided herein is a method for SNP detection and analysis based on high-throughput sequencing, comprising designing a probe, pre-amplification and biotin labeling, hybridization, ligation, barcode specific primer extension, sequencing and analyzing the SNP locus. A probe set is for the analysis is also provided.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 7, 2020
    Assignees: CAPITALBIO CORPORATION, TSINGHUA UNIVERSITY
    Inventors: Dong Wang, Hui Wang, Yan Zhang, Guangxin Xiang, Yimin Sun, Wanli Xing, Jing Cheng
  • Patent number: 10697016
    Abstract: Provided herein are methods and compositions for the detection of silent carriers of chromosomal deletion alleles in a human subject using haploid cells (e.g., sperm cells or egg cells) derived from the subject. The methods provided herein allow for the detection of silent (2+0) carriers of SMA, where the individual has a deletion of the SMN1 gene on one chromosome 5 homolog and two or more copies of the SMN1 gene on the other chromosome 5 homolog.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 30, 2020
    Assignee: ATHENA DIAGNOSTICS, INC.
    Inventors: David A. Hill, Matthew Evans, Corey D. Braastad
  • Patent number: 10697021
    Abstract: The present invention provides a method of diagnosing a breast cancer central nervous system (CNS) metastasis in a subject, comprising determining the expression level of at least one biomarker in a subject-derived brain or breast tissue comparing the subject-derived expression level with a normal control level obtained from normal brain or breast cells; and correlating an increase or decrease of the subject-derived expression level as compared to the normal control level to a diagnosis of a breast cancer CNS metastasis. The present invention also provides a method for the treatment of a breast cancer CNS metastasis in a subject comprising administering to the subject an inhibitor of an overexpressed gene associated with CNS metastasis.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: June 30, 2020
    Assignee: The Translational Genomics Research Institute
    Inventor: Bodour Salhia
  • Patent number: 10689704
    Abstract: The present invention provides method for predicting risk of cervical shortening, methods for predicting risk of preterm labour (PTL), and methods for characterising a pregnant subject having a history of previous PTL, mid-trimester loss or cervical cone biopsy as being in need of surveillance and/or intervention to prevent preterm labour, comprising determining the expression level of one or more of the miRNA molecules identified in Table 1 or Table 2 extracted from a biological sample obtained from said subject and comparing to a control value. Biochips and kits for use in carrying out the methods of the invention are also provided.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: June 23, 2020
    Assignee: Imperial College of Science, Technology and Medicine
    Inventors: Joanna Cook, Philip Bennett, Vasiliki Terzidou, David MacIntyre
  • Patent number: 10689701
    Abstract: Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: June 23, 2020
    Assignee: Duke University
    Inventors: Ephraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn
  • Patent number: 10692605
    Abstract: A method, system, and computer program product are provided for generating a predictive model. A processor(s) obtains a raw data set (peptide libraries) of patients designated as diagnosed/pre-diagnosed with a condition or not diagnosed with the condition. The processor(s) segments the raw data set into a pre-defined number of groups and separates out a holdout group. The processor(s) performs a principal component analysis on the remaining groups to identify, based on a frequency of features in the remaining groups, common features (principal components) in the remaining groups and weighs the common features based on frequency of occurrence. The processor(s) determines a smallest number of the principal components that yields a pre-defined level of validation accuracy. The processor(s) generates a predictive model, by utilizing the smallest number for a best fit in a logistic regression model. The predictive model provides binary outcomes.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 23, 2020
    Assignee: International Business Machines Corporation
    Inventors: Avijit Chatterjee, Wendy Wang
  • Patent number: 10663459
    Abstract: The present invention relates to a composition for detecting microbial contamination comprising a preparation for detecting nucleases, and a use thereof. A probe for measuring nucleic acid double-stranded nucleases, according to the present invention, may detect the comprehensive nucleic acid degradation capability of nucleases, whereby it is possible to quickly and precisely detect and quantify live microorganisms in a sample in a simple manner. Moreover, since the probe of the present invention is characterized in that signals of fluorescence consistently increase; is capable of measuring live microorganisms; and consists of a double-stranded nucleic acid, the probe is excellent for storage in a kit or a cartridge. As such, it is expected that the probe of the present invention may be used to easily and simply measure and compare the degree of contamination of microorganisms in an environment.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 26, 2020
    Assignee: Haesung Bio Co., Ltd.
    Inventors: Kyoung Sook Park, Bong Hyun Chung, Kyung Jin Lee, Byung Kwon Kim, So Yeon Yi, Jung Sun Kwon, Ui Jin Lee, Seong U. Kim, Ho Jae Lee
  • Patent number: 10662463
    Abstract: This invention provides methods of using labeled nucleotide polyphosphate analogues to detect the identity or presence of a nucleotide at certain positions in nucleic acid sequences with single molecule sensitivity using nanopore detection, nucleotides and primer-conjugated nanopore proteins for use in such methods, and processes for producing such nucleotides and primer-conjugated nanopore proteins.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: May 26, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jingyue Ju, Youngjin Cho, Shiv Kumar, Sergey Kalachikov, Chuanjuan Tao, Minchen Chien, James J. Russo
  • Patent number: 10662462
    Abstract: The present disclosure relates, in some aspects, to the field of nucleic acid detection. Disclosed herein are methods and compositions for detecting nucleic acids using synthetic single-stranded ribonucleic acids (RNAs). In certain embodiments, synthetic single-stranded RNAs are used to detect therapeutic nucleic acids, such as therapeutic deoxyribonucleic acids (DNAs) and/or therapeutic ribonucleic acids (RNAs).
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: May 26, 2020
    Assignee: Biogen MA Inc.
    Inventors: Kirk M. Brown, Denitza Raitcheva
  • Patent number: 10655173
    Abstract: The present invention relates to molecular microscopy or volumetric imaging by proximal unique molecular identifiers (“UID”) reaction (“VIPUR”) microscopy methods to record the cellular co-localization and/or spatial distributions of arbitrary nucleic acid sequences, or other biomolecules tagged with nucleic sequences. The method involves one or both of two DNA sequence-components such as an ?-UID, which may identify the targeted sequences-of-interest themselves and/or spatial beacons relative to which their distances are measured, and a- ?-UID, which labels ?-UID association events.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: May 19, 2020
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Joshua Asher Weinstein, Aviv Regev
  • Patent number: 10648103
    Abstract: Provided herein, in some embodiments, are novel compositions and improved methods for nucleic acid manipulation and analysis that can be applied to multiplex nucleic acid sequencing. In certain embodiments, the novel compositions and methods presented herein are more cost effective, more conducive to automation, and faster than traditional approaches. Also provided herein are novel blocking nucleic acids.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: May 12, 2020
    Assignee: INVITAE CORPORATION
    Inventor: Eric Olivares
  • Patent number: 10640829
    Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: May 5, 2020
    Assignee: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Paul A. Lyons, Kenneth G. C. Smith, Eoin F. McKinney, Daniele Biasci, James Lee
  • Patent number: 10636512
    Abstract: Provided herein are systems and methods for generating an immune-oncology profile from a biological sample. The immune-oncology profile can include the proportion or percentage of immune cells, expression of immune escape genes, and/or mutational burden. The immune-oncology profile may allow the generation of classifiers for making prognostic or diagnostic predictions.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: April 28, 2020
    Assignee: COFACTOR GENOMICS, INC.
    Inventors: Ryan J. Bloom, Jon R. Armstrong
  • Patent number: 10633706
    Abstract: A method of diagnosing a disease associated with a DNA repeat sequence is disclosed. The method comprises: (a) determining the number of repeats of a DNA sequence in DNA molecules of a sample of the subject; and (b) determining the CpG methylation status of the DNA molecules, wherein the number of repeats of the DNA sequence and the CpG methylation status of the DNA molecules is indicative of the disease.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: April 28, 2020
    Assignees: Ramot at Tel-Aviv University Ltd., Rheinisch-Westfälische Technische Hochschule (RWTH) Aaachen
    Inventors: Yuval Ebenstein, Elmar Weinhold, Assaf Grunwald, Tslil Gabrieli
  • Patent number: 10632468
    Abstract: An apparatus configured for improving retention of non-adherent cells is disclosed. The apparatus includes a plate that includes a number of elements having a first surface energy arranged in an array with an overlay, on the plate, having a second surface energy. The first surface energy results in a hydrophilic surface and the second surface energy results in a hydrophobic surface. A diameter of the elements is at least 1 mm. A height of the overlay having the second surface energy, which results in a hydrophobic surface, is between 5% and 100% of the diameter of the elements. The apparatus also includes a wall circumferential to the plate. A method for performing multiple reactions with the apparatus is also disclosed.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: April 28, 2020
    Assignee: Curiox Biosystems Pte Ltd.
    Inventors: Namyong Kim, Siah Chong Cheong, Hanwen Melvin Lye, Mark Siew Peng Phong, Li Li, Teow Soon Seah
  • Patent number: 10626463
    Abstract: The present invention provides a method of predicting the risk of reoccurrence of melanoma in a patient from whom melanoma tissue was previously removed which comprises the following: a. obtaining a RNA-containing sample of the previously removed melanoma tissue containing RNA from the patient; b. treating the sample to determine from the RNA contained in the sample the level of expression of a plurality of preselected genes; and c. comparing the level of expression of each gene of the plurality of pre-selected genes to a predetermined reference level of expression for each such gene; wherein a higher level of expression of the plurality of pre-selected genes in the sample as compared with the predetermined reference level of expression of such genes indicates that the patient has a reduced risk of reoccurrence of melanoma.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: April 21, 2020
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Yvonne Saenger, Shanthi Sivendran, Rui Chang, Analisa Difeo
  • Patent number: 10626442
    Abstract: The invention provides methods, compositions, kits and devices for the detection of target molecules. In some embodiments, the invention allows for multiplexed target molecule detection.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 21, 2020
    Assignee: Roche Sequencing Solutions, Inc.
    Inventor: Garry P. Nolan
  • Patent number: 10618943
    Abstract: The invention provides ubiquitin variants that specifically bind to HECT E3 ligases, and methods of using these variants to modulate the activity of HECT E3 ligases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: April 14, 2020
    Inventors: Wei Zhang, Sachdev Sidhu
  • Patent number: 10619204
    Abstract: Embodiments of the present disclosure relate to methods for capturing and amplifying target polynucleotides on a solid surface, in particular in a well in a microarray, wherein the microarray may comprise a) a substrate comprising at least one well, a surface surrounding the well and an inner well surface; b) a first layer covering the inner well surface and comprising at least one first capture primer pair; and c) a second layer covering the first layer and the surface surrounding the well.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: April 14, 2020
    Assignee: Illumina Cambridge Limited
    Inventors: Kevin L. Gunderson, Jingwei Bai, Matthew William Kellinger, John M. Beierle, Jonathan Mark Boutell, Roberto Rigatti, Maria Candelaria Rogert Bacigalupo, Boyan Boyanov, Klaus Maisinger
  • Patent number: 10620218
    Abstract: The present disclosure relates to a method for predicting a recurrence and a progression of an urothelial cancer patient after a treatment including steps as follows. A urine sample is obtained from a subject. The urine sample is performing a serially centrifugation step to obtain a third precipitate. The third precipitate is resuspended with an extraction solvent to obtain a third mixture, and the third mixture is centrifuged to obtain a fourth supernatant. The fourth supernatant is analyzed by a mass spectrometry to detect whether there is a particular peptide therein.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: April 14, 2020
    Assignee: China Medical University
    Inventor: Shih-Yi Lin
  • Patent number: 10612017
    Abstract: The invention provides particle compositions having applications in nucleic acid analysis. Nucleic acid polymer particles of the invention allow polynucleotides to be attached throughout their volumes for higher loading capacities than those achievable solely with surface attachment. In one aspect, nucleic acid polymer particles of the invention comprise polyacrylamide particles with uniform size distributions having low coefficients of variations, which result in reduced particle-to-particle variation in analytical assays. Such particle compositions are used in various amplification reactions to make amplicon libraries from nucleic acid fragment libraries.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: April 7, 2020
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Wolfgang Hinz, John Leamon, David Light, Jonathan M. Rothberg
  • Patent number: 10611824
    Abstract: Some embodiments described herein relate to solid-support based processes for the functionalization of immunoglobulins through the use of transglutaminase. Also provided are solid support compositions with bound antibody. The methods can be used, for example, in manufacturing processes or in drug screening.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 7, 2020
    Assignee: Innate Pharma
    Inventor: Delphine Bregeon
  • Patent number: 10604802
    Abstract: Disclosed herein are compositions and methods related to the elimination of molecules of a selected sequence from a nucleic acid sample or from an sequence dataset resulting from the sequencing of a sample, for example to exclude such molecules from downstream analysis or sequencing, or to exclude such sequences from a downstream data set.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: March 31, 2020
    Assignee: JUMPCODE GENOMICS, INC.
    Inventors: Keith Brown, Peter Dansky
  • Patent number: 10598663
    Abstract: The present invention relates to methods and biomarkers (e.g., protein biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer, providing a prognosis to colorectal cancer patients, and in companion diagnostics.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: March 24, 2020
    Assignee: Oslo Universitetssykehus HF
    Inventors: Ragnhild A. Lothe, Jarle Bruun, Matthias Kolberg, Rolf Inge Skotheim, Guro Elisabeth Lind, Arild Nesbakken
  • Patent number: 10597650
    Abstract: Compositions and methods are provided for ligating polynucleotides having a length that is greater than 8 nucleotides on an RNA splint. The ligation reaction provides consistent results in high or low ATP concentrations. The reaction can occur rapidly and is generally at least 10 fold more efficient than T4DNA ligase under optimal conditions for T4DNA ligase and the reaction time is less than 6 hours for example, less than 1 hour.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 24, 2020
    Assignee: New England Biolabs, Inc.
    Inventors: Gregory Lohman, Thomas C. Evans, Larry A. McReynolds
  • Patent number: 10597710
    Abstract: Compositions and methods are provided for ligating polynucleotides having a length that is greater than 8 nucleotides on an RNA splint. The ligation reaction provides consistent results in high or low ATP concentrations. The reaction can occur rapidly and is generally at least 10 fold more efficient than T4DNA ligase under optimal conditions for T4DNA ligase and the reaction time is less than 6 hours for example, less than 1 hour.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: March 24, 2020
    Assignee: New England Biolabs, Inc.
    Inventors: Gregory Lohman, Thomas C. Evans, Jr., Larry A. McReynolds